---
title: "Absci (ABSI) news: offering, merger and settlement"
url: "https://aibio.space/companies/absci/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "ABSI offering, merger and settlement news. Absci news for investors: Absci uses generative AI and synthetic biology data to design antibodies, led by…"
---

Desk view · Opinion · Updated Oct 22, 2026

## Absci has the cash; ABS-201 still has to grow hair

Absci is now a funded single-asset bet on a prolactin receptor antibody, with clean phase 1 safety and a long half-life but no efficacy data. The interim hair loss readout due in the second half of 2026 will decide how much the AI design story is worth.

Read the full desk view

aibio.space Investor Rank · Opinion

**3** /10 Negative view

Funded into 2028, but ABS-201 has no efficacy data yet and both lead programs share one target, so the hair loss readout carries the company.

- **Technology**: 0/2

- **Odds**: 0/2

- **Balance sheet**: 2/2

- **Risk**: 0/2

- **Momentum**: 1/2

Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. [How the rank works](https://aibio.space/disclosures/#rank).

- **Technology**: **Unproven in patients.** ABS-201 showed clean single-dose safety and a half-life of at least 65 days, but no efficacy data yet.

- **Odds**: **Phase 1 base rates apply.** BIO data put approval odds from phase 1 at 7.9%, and the PRLR mechanism is new in hair loss.

- **Balance sheet**: **Funded into 2H 2028.** About $201 million at June 30 after a $100 million raise, against a quarterly loss near $33 million.

- **Main risk**: **Single-target pipeline.** Both lead programs block the prolactin receptor, so one mechanism carries the company.

- **Watch next**: **Interim HEADLINE hair data.** Absci guides to the second half of 2026, with Q3 results due Nov. 12.

## Top news on Absci

1. 2026-08-11 Financings [Absci cash rises to $201 million after June raise; Lilly invests $40 million](https://aibio.space/news/absci-cash-rises-201-million-after-june-raise-lilly-invests-40-million/) The company extended its runway into the second half of 2028. Lilly's stake carries no rights to the ABS-201 antibody.
2. 2026-06-24 Financings [Absci raises $100 million at $7.41 a share with Eli Lilly among buyers](https://aibio.space/news/absci-raises-100-million-7-41-share-eli-lilly-among-buyers/) The offering followed interim phase 1 data for ABS-201. Proceeds fund the antibody's hair loss and endometriosis programs.
3. 2025-11-04 Mergers [Absci and Totient sellers agree final milestone payout under 2021 merger agreement](https://aibio.space/news/absci-totient-sellers-agree-final-milestone-payout-under-2021-merger/) A letter agreement dated October 31, 2025 settles all potential milestone payments from Absci's 2021 Totient deal. Former Totient stockholders get about $7.6 million, and Absci gets about $8.7 million.

## Dates

**Nov. 12, 2026**
Third-quarter 2026 results and business update [Source](https://investors.absci.com/news-releases/news-release-details/absci-report-business-updates-and-third-quarter-2026-financial)

**2H 2026**
Interim proof-of-concept data for ABS-201 in pattern hair loss [Source](https://investors.absci.com/news-releases/news-release-details/absci-reports-business-updates-and-second-quarter-2026-financial)

**Early 2027**
Full 26-week proof-of-concept readout for ABS-201 in pattern hair loss [Source](https://investors.absci.com/news-releases/news-release-details/absci-reports-business-updates-and-second-quarter-2026-financial)

**Mid-2027**
Planned start of the STORYLINE phase 2 trial in endometriosis [Source](https://investors.absci.com/news-releases/news-release-details/absci-announces-preliminary-details-phase-2-storylinetm-trial-ai)

## The money

$201.1 million in cash, cash equivalents and marketable securities at June 30, 2026 (Q2 2026), including $93.6 million net from a June offering. Runway guided into the second half of 2028. [Source](https://investors.absci.com/news-releases/news-release-details/absci-reports-business-updates-and-second-quarter-2026-financial)

## Risks on the record

- The pipeline is concentrated on one target: ABS-201 and ABS-202 both block the prolactin receptor. [Source](https://investors.absci.com/news-releases/news-release-details/absci-reports-business-updates-and-second-quarter-2026-financial)
- ABS-201 has no reported efficacy data; human data so far are single-dose safety and pharmacokinetics in 32 healthy adults. [Source](https://investors.absci.com/news-releases/news-release-details/absci-announces-positive-interim-phase-1-data-headlinetm-trial)
- The endometriosis phase 2 start moved from Q4 2026 to mid-2027, contingent on regulatory clearance and HEADLINE data. [Source](https://investors.absci.com/news-releases/news-release-details/absci-announces-preliminary-details-phase-2-storylinetm-trial-ai)

## Questions investors ask

### What is aibio.space's Investor Rank for Absci?

3 out of 10, our negative view. Funded into 2028, but ABS-201 has no efficacy data yet and both lead programs share one target, so the hair loss readout carries the company. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. [Source](https://aibio.space/disclosures/#rank)

### What is Absci's ABS-201?

ABS-201 is an antibody against the prolactin receptor that Absci designed with its generative AI platform. It is in a phase 1/2a trial for pattern hair loss, and Absci plans a phase 2 trial in endometriosis. [Source](https://investors.absci.com/news-releases/news-release-details/absci-announces-preliminary-details-phase-2-storylinetm-trial-ai)

### When will Absci report ABS-201 hair loss efficacy data?

Absci guides to interim proof-of-concept data from the HEADLINE trial in the second half of 2026 and a full 26-week readout in early 2027. [Source](https://investors.absci.com/news-releases/news-release-details/absci-reports-business-updates-and-second-quarter-2026-financial)

### Did Eli Lilly invest in Absci?

Yes. Absci said Lilly made a $40 million strategic equity investment in 2026 that gives Lilly no rights to ABS-201. Lilly was among the named buyers in Absci's $100 million offering priced on June 24, 2026. [Source](https://investors.absci.com/news-releases/news-release-details/absci-reports-business-updates-and-second-quarter-2026-financial)

### How much cash does Absci have?

Absci had $201.1 million in cash, cash equivalents and marketable securities at June 30, 2026. It expects that to fund operations into the second half of 2028. [Source](https://investors.absci.com/news-releases/news-release-details/absci-reports-business-updates-and-second-quarter-2026-financial)

### When does Absci's endometriosis trial start?

Absci said on Sept. 24, 2026 that it expects the phase 2 STORYLINE trial of ABS-201 in endometriosis to start in mid-2027, pending regulatory clearance and HEADLINE data. It had earlier guided to the fourth quarter of 2026. [Source](https://investors.absci.com/news-releases/news-release-details/absci-announces-preliminary-details-phase-2-storylinetm-trial-ai)

### What is the latest Absci (ABSI) stock news?

Our latest story on Absci, dated Aug 11, 2026: "Absci cash rises to $201 million after June raise; Lilly invests $40 million". The company extended its runway into the second half of 2028. Lilly's stake carries no rights to the ABS-201 antibody. [Source](https://aibio.space/news/absci-cash-rises-201-million-after-june-raise-lilly-invests-40-million/)

### What is Absci's latest stock offering or financing news?

Our latest financing story, dated Aug 11, 2026: "Absci cash rises to $201 million after June raise; Lilly invests $40 million". The company extended its runway into the second half of 2028. Lilly's stake carries no rights to the ABS-201 antibody. [Source](https://aibio.space/news/absci-cash-rises-201-million-after-june-raise-lilly-invests-40-million/)

### Who were the underwriters or placement agents on Absci's offering?

From our story: Jefferies, J.P. Morgan, TD Cowen and Guggenheim Securities were joint book-running managers. [Source](https://aibio.space/news/absci-cash-rises-201-million-after-june-raise-lilly-invests-40-million/)

### How long will Absci's cash last?

From our story of Aug 11, 2026: The company now expects its cash to fund operations into the second half of 2028. [Source](https://aibio.space/news/absci-cash-rises-201-million-after-june-raise-lilly-invests-40-million/)

### Is Absci being acquired or merging?

Our latest merger story, dated Nov 4, 2025: "Absci and Totient sellers agree final milestone payout under 2021 merger agreement". A letter agreement dated October 31, 2025 settles all potential milestone payments from Absci's 2021 Totient deal. Former Totient stockholders get about $7.6 million, and Absci gets about $8.7 million. [Source](https://aibio.space/news/absci-totient-sellers-agree-final-milestone-payout-under-2021-merger/)

### What is Absci's market cap?

We do not publish live share prices. In its annual report, Absci Corporation put the market value of shares held by non-affiliates (public float) at $303.8 million as of Jun 30, 2025. Source

### Is Absci a smaller reporting company?

SEC records list Absci Corporation's filer category as: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company. Source

### Where is Absci headquartered?

SEC records list its business address as 18105 SE MILL PLAIN BLVD, VANCOUVER, WA, 98683. Source

### When does Absci's fiscal year end?

Absci Corporation's fiscal year ends on December 31, per SEC records. Source

## Legal and investor matters

Checked against Absci filings and press releases. Allegations are allegations; nothing here is a finding of fault. Reviewed Oct 25, 2026.

Absci's 10-Q filed 2026-08-11 (Part II, Item 1, Legal Proceedings) states that Absci is not currently a party to any material litigation or other legal proceedings. [Source](https://www.sec.gov/Archives/edgar/data/1672688/000167268826000136/absi-20260630.htm)

1. 2026-06-24 Financing Absci prices 13.5 million share public offering at $7.41 Absci Corporation entered into an underwriting agreement on 2026-06-24 for 13,495,277 shares of common stock at $7.41 per share, with Jefferies, J.P. Morgan, TD Securities and Guggenheim as underwriters. The company estimated net proceeds of about $93.5 million. It said it intends to fund ABS-201 development in androgenetic alopecia and endometriosis, plus general corporate purposes. The offering used its Form S-3 shelf. [Absci Form 8-K filed 2026-06-24](https://www.sec.gov/Archives/edgar/data/1672688/000119312526281143/d139233d8k.htm)
2. 2025-07-24 Financing Absci prices 16.7 million share public offering at $3.00 Absci Corporation entered into an underwriting agreement on 2025-07-24 for 16,670,000 shares of common stock at a public offering price of $3.00 per share, with Morgan Stanley, J.P. Morgan, Jefferies and TD Securities as underwriters. The underwriters also received a 30-day option for up to 2,500,500 more shares. The company estimated net proceeds of about $46.7 million, or $53.7 million if the option was exercised in full. [Absci Form 8-K filed 2025-07-25](https://www.sec.gov/Archives/edgar/data/1672688/000119312525165466/d65613d8k.htm)

## Pipeline

| Program | Indication | Stage |
|---|---|---|
| ABS-201 (anti-PRLR antibody) | Androgenetic alopecia (pattern hair loss) | Phase 1/2a (HEADLINE), multiple-dose portion ongoing [Source](https://investors.absci.com/news-releases/news-release-details/absci-reports-business-updates-and-second-quarter-2026-financial) |
| ABS-201 (anti-PRLR antibody) | Endometriosis-associated pain | Phase 2 (STORYLINE) planned, start expected mid-2027 [Source](https://investors.absci.com/news-releases/news-release-details/absci-announces-preliminary-details-phase-2-storylinetm-trial-ai) |
| ABS-202 (anti-PRLR antibody) | Undisclosed inflammation and immunology indication | Preclinical [Source](https://investors.absci.com/news-releases/news-release-details/absci-reports-business-updates-and-second-quarter-2026-financial) |

Opinion · Devil's advocate

## Fact-check-o-meter

Some gaps

Absci's filings match its numbers, but its releases lean harder on thin early data

Absci's cash figures and risk language line up between its releases and its 10-Q. The gaps are in emphasis: a 'positive' label on blinded, single-dose safety data, and an endometriosis start date that moved from the fourth quarter of 2026 to mid-2027 without the September release saying so. ABS-201 still has no human efficacy data.

1. Press release vs filing · weight medium "Positive" phase 1 data are blinded safety and PK only **The company said:** "today reported positive interim Phase 1 data from its first-in-human trial of ABS-201" [source](https://www.sec.gov/Archives/edgar/data/1672688/000167268826000118/exhibit991-26x06x23pr.htm) **The record says:** The same release says the data cover 32 healthy adults in single ascending dose cohorts and that "Blinded, aggregate interim data suggest study drug was well tolerated and exhibited a favorable safety and tolerability profile." The 10-Q adds that "interim clinical data may change as additional data become available." [source](https://www.sec.gov/Archives/edgar/data/1672688/000167268826000136/absi-20260630.htm) **Our view:** Nothing here is wrong, but "positive" describes a blinded tolerability and half-life readout in healthy volunteers, with no hair growth measured yet. The first real test is the interim proof-of-concept data the company guides to the second half of 2026.
2. Press release vs filing · weight medium Endometriosis phase 2 start moved without comment **The company said:** "Absci anticipates initiation of this Phase 2 clinical trial for endometriosis in mid-2027." [source](https://investors.absci.com/news-releases/news-release-details/absci-announces-preliminary-details-phase-2-storylinetm-trial-ai) **The record says:** The 10-Q filed on August 11, 2026 said: "we anticipate initiating a Phase 2 clinical trial evaluating ABS-201 in endometriosis in the fourth quarter of 2026, subject to review of available data, regulatory considerations and other factors, with potential proof-of-concept data in the second half of 2027." [source](https://www.sec.gov/Archives/edgar/data/1672688/000167268826000136/absi-20260630.htm) **Our view:** The September release gave a new start date but did not say that the earlier guidance was the fourth quarter of 2026, or why it moved. A slip of about two quarters would normally push back any endometriosis proof-of-concept readout, although the September release gave no readout timing, and the release adds that dose levels "will be confirmed following review of HEADLINE data."
3. Science · weight medium Efficacy rests on preclinical work; hair count is a secondary endpoint **The company said:** "In preclinical studies, the antibody demonstrated statistically significant superior hair regrowth compared to minoxidil in a preclinical mouse model." [source](https://www.sec.gov/Archives/edgar/data/1672688/000167268826000118/exhibit991-26x06x23pr.htm) **The record says:** ClinicalTrials.gov lists the primary outcome as "Incidence rate of treatment-emergent adverse events (TEAEs) and serious TEAEs", with target area hair count and width as secondary outcomes from "Baseline to Week 26" in the MAD cohorts. The record also lists safety monitoring of "change in neurobehavioral symptoms (PHQ-9 and GAD-7)" and an estimated primary completion of July 2028. [source](https://clinicaltrials.gov/study/NCT07317544) **Our view:** A mouse result against minoxidil is not evidence of human hair growth. The trial is placebo-controlled and blinded, which is a strength, but its registered primary outcome is safety, so the 2026 interim and early 2027 readouts on hair count will be small, secondary-endpoint looks.
4. Press release vs filing · weight low Runway claim is consistent with the 10-Q **The company said:** "Absci now believes its cash, cash equivalents, and marketable securities will be sufficient to fund its operating plans into the second half of 2028." [source](https://www.sec.gov/Archives/edgar/data/1672688/000167268826000134/exhibit991-2026q210xqpr.htm) **The record says:** The 10-Q reports an accumulated deficit of $687.6 million and states that cash "will be sufficient to meet our operating expenses, working capital and capital expenditure needs over at least the next 12 months following the date of this filing." It does not contain going-concern doubt. [source](https://www.sec.gov/Archives/edgar/data/1672688/000167268826000136/absi-20260630.htm) **Our view:** The $201.1 million cash figure and the runway claim match the filing. The 10-Q's 12-month statement is the standard formal test, not a contradiction, though a net loss of $33.2 million in the quarter shows how the runway depends on spending staying near current levels.
5. Legal and disclosure record · weight low No litigation or enforcement disclosed **The record says:** Item 1, Legal Proceedings: "We are not currently a party to any material litigation or other legal proceedings." [source](https://www.sec.gov/Archives/edgar/data/1672688/000167268826000136/absi-20260630.htm) **Our view:** No securities litigation or enforcement disclosed in the latest filing.

Documents we compared

- [Absci Form 10-Q for the quarter ended June 30, 2026](https://www.sec.gov/Archives/edgar/data/1672688/000167268826000136/absi-20260630.htm) 2026-08-11
- [Absci second quarter 2026 results release (8-K Exhibit 99.1)](https://www.sec.gov/Archives/edgar/data/1672688/000167268826000134/exhibit991-2026q210xqpr.htm) 2026-08-11
- [Absci interim phase 1 HEADLINE data release (8-K Exhibit 99.1)](https://www.sec.gov/Archives/edgar/data/1672688/000167268826000118/exhibit991-26x06x23pr.htm) 2026-06-24
- [Absci STORYLINE phase 2 preliminary details release](https://investors.absci.com/news-releases/news-release-details/absci-announces-preliminary-details-phase-2-storylinetm-trial-ai) 2026-09-24
- [ClinicalTrials.gov NCT07317544 (HEADLINE)](https://clinicaltrials.gov/study/NCT07317544) 2026-09-03

This is opinion. We compare the company's own announcements with its filings and the scientific record, and link every source. It is not an allegation of wrongdoing and not investment or legal advice. Legal items list only matters disclosed in filings or by courts and regulators. Checked Oct 23, 2026. Companies can respond through our [right of reply](https://aibio.space/reputation/#reply).

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ABSI on TradingView](https://www.tradingview.com/symbols/NASDAQ-ABSI/).

## SEC filings and registration

- **SEC name**: Absci Corp

- **CIK**: 1672688

- **Industry (SIC)**: Services-Commercial Physical & Biological Research (8731)

- **US tickers**: ABSI (Nasdaq)

- **Fiscal year ends**: December 31

- **Filer category**: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

- **Business address**: 18105 SE MILL PLAIN BLVD, VANCOUVER, WA, 98683

- **Phone**: (360) 949-1041

- **Shares outstanding**: 171,614,010 as of 2026-07-31 (10-Q filed 2026-08-11)

- **Former names**: AbSci, LLC

### Recent filings (8-K and 6-K are the company's own announcements)

- [10-Q](https://www.sec.gov/Archives/edgar/data/1672688/000167268826000136/absi-20260630.htm) filed 2026-08-11
- [8-K](https://www.sec.gov/Archives/edgar/data/1672688/000167268826000134/absc-20260811.htm) filed 2026-08-11
- [8-K](https://www.sec.gov/Archives/edgar/data/1672688/000119312526281143/d139233d8k.htm) filed 2026-06-24
- [424B5](https://www.sec.gov/Archives/edgar/data/1672688/000119312526281131/d76291d424b5.htm) filed 2026-06-24
- [8-K](https://www.sec.gov/Archives/edgar/data/1672688/000167268826000118/absc-20260624.htm) filed 2026-06-24
- [8-K](https://www.sec.gov/Archives/edgar/data/1672688/000167268826000095/absc-20260604.htm) filed 2026-06-05
- [10-Q](https://www.sec.gov/Archives/edgar/data/1672688/000167268826000088/absi-20260331.htm) filed 2026-05-07
- [8-K](https://www.sec.gov/Archives/edgar/data/1672688/000167268826000086/absc-20260507.htm) filed 2026-05-07

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001672688), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/absci/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Absci (ABSI) news: offering, merger and settlement", 2026-10-31, https://aibio.space/companies/absci/